Danaher stock: CEO outlines path to faster growth at UBS conference

Danaher stock traded at 209.35 euros on Lang & Schwarz at 12:39 CET on Tuesday, November 10, 2026.

At the UBS Global Healthcare Conference on Monday, November 9, CEO Julie Sawyer Montgomery presented a strategy aimed at moving Danaher from mid-single-digit core growth, excluding respiratory, toward high-single-digit growth over the next several years. Investing.com reported on the conference on Tuesday.

Four levers shape the strategy

Montgomery identified commercial execution, innovation, talent and capital allocation as the main levers. Danaher wants to increase cross-selling across its operating companies and use its Danaher Business System to improve execution after acquisitions.

The company set a 4% to 5% core-growth starting point for 2027, excluding respiratory. Management said stronger customer coverage, new products and share gains could lift growth toward the high-single-digit range over a three- to five-year period.

AI and bioprocessing lead opportunities

Danaher sees AI drug discovery and autonomous science as a potential share-gain opportunity. The company has launched an autonomous laboratory at Abcam and cited partnerships with Anthropic and NVIDIA as part of its technology push.

Cytiva remains a central part of the biotechnology platform. Management said equipment orders rose at a mid-teens rate in the third quarter and typically convert into revenue over nine to twelve months. Danaher also estimates a 1 billion US dollar reshoring opportunity, with the main revenue contribution expected in 2028 and later.

Montgomery said roughly 100 originator products coming off patent could support biosimilar demand. She also said Cytiva is specified into about 90% of monoclonal-antibody volume, supporting the company's confidence in its long-term position.

Diagnostics and China add support

In life sciences, management highlighted high-single-digit growth at SCIEX, improving momentum at Abcam and double-digit growth in clinical applications at IDT. The company said Abcam has grown for three consecutive quarters after commercial investment.

Diagnostics remains another focus. Beckman Coulter has fully launched its DxI 9000 immunoassay platform in the United States, while Cepheid continues to grow at a double-digit rate outside respiratory testing. Danaher is also building a neurodegenerative testing portfolio aimed at the Alzheimer's market.

China delivered high-single-digit growth in the third quarter, including double-digit growth in biotechnology and mid-single-digit growth in life sciences, according to management. Danaher said diagnostics also returned to growth in the country as healthcare reforms moved closer to normalization.

Investors weigh execution against valuation

The conference message gives Danaher a broader recovery narrative, but delivery remains the central issue for investors. The company must convert Cytiva orders, commercial investments and AI initiatives into sustained revenue and profit growth while integrating Masimo and pursuing selective acquisitions.

Danaher stock remains part of the broader US equity market, tracked through the S&P 500.

More news and analyses on Danaher stock.